Image pharmaphorum Editor Views & Analysis How will NICE fare in a post-Brexit world? NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Views & Analysis From representation to empowerment: Putting patients at the ... Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this. Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Views & Analysis A year on: pandemic driven trends in HCP engagement IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. Load more results
Views & Analysis How will NICE fare in a post-Brexit world? NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU?
Views & Analysis From representation to empowerment: Putting patients at the ... Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this.
Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis A year on: pandemic driven trends in HCP engagement IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.